Phase I/II Study of the Toxicity, Pharmacokinetics, and Activity of the HIV Protease Inhibitor SC-52151-Reference-Cited by-同舟云学术

Phase I/II Study of the Toxicity, Pharmacokinetics, and Activity of the HIV Protease Inhibitor SC-52151

Published:1997-05 Issue:1 Volume:15 Page:28-34
ISSN:1077-9450
Container-title:Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
language:en
Short-container-title:Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Author:

Fischl Margaret A.,Richman Douglas D.,Flexner Charles,Para Michael F.,Haubrich Richard,Karim Aziz,Yeramian# Patrick,Holden-Wiltse# Jeanne,Meehan# Patricia M.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Virology,Immunology,Immunology and Allergy

Reference18 articles.

1. Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere

2. Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors

3. HIV-1 Protease inhibitors: Their development, mechanism of action and clinical potential

4. Rational Design of Peptide-Based HIV Proteinase Inhibitors

5. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ADME, Pharmacokinetic Scaling, Pharmacodynamic and Prediction of Human Dose and Regimen of Novel Antiviral Drugs;Pharmaceutics;2023-04-11

2. Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID‐19 Therapeutic Development;Clinical Pharmacology & Therapeutics;2020-11-21

3. Lipids and Surfactants: The Inside Story of Lipid-Based Drug Delivery Systems;Critical Reviews™ in Therapeutic Drug Carrier Systems;2018

4. Evaluation of preclinical formulations for a poorly water-soluble compound;International Journal of Pharmaceutics;2016-09

5. Pharmacokinetics of antiretrovirals in mucosal tissue;Expert Opinion on Drug Metabolism & Toxicology;2015-03-22